Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGC001 in anterior STEMI undergoing PCI
NCT07091929Phase 1Completed
- Sponsor
- Sungen Biomedical
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anterior myocardial infarction (AWMI) comparing SGC001 with Placebo (2 arms). Primary endpoints: Adverse Events at 30 days, Serious Adverse Events at 30 days and 1 more. Started Jan 2025; status: completed.
02
Drugs
SGC001
03
Conditions
anterior myocardial infarction (AWMI)
Beyond the preview
Go deeper on NCT07091929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091929.